Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
43.44%
Net Margin
49.61%
Efficiency Metrics
Revenue per Expense Ratio
1.77
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.2300000000
Balance Sheet Analysis
Current Ratio
0.81
Cash Ratio
0.35
Working Capital
$-1.14M
Debt to Equity
0.02
Debt to Assets
1.66%
Equity Ratio
68.85%
Cash Flow Analysis
Operating Cash Flow Ratio
52.19%
Free Cash Flow Ratio
52.19%
CapEx to Revenue
0.00%
Dividends Paid
$3.98M
Stock Buybacks
$475.00K
Total Shareholder Returns
$4.45M
Cash Position Change
-956,085,600.0%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
140.67%
Net Income
118.72%
EPS
118.70%
Operating Income
116.40%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
420.24%
Operating Cash Flow
-2.07%
Free Cash Flow
-2.07%
Balance Sheet Health
Assets
1.58%
Debt
46.34%
Book Value per Share
-1.67%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-0.77%
Shares Outstanding
0.71%
Long Term Trends
3Y Revenue/Share
21.79%
5Y Revenue/Share
249.39%
3Y Dividend/Share
-1.61%
5Y Dividend/Share
-30.41%